Reported about 1 year ago
As the local COVID-19 situation worsens in Taiwan, reports of a significant increase in hospitalizations have emerged, with doctors complaining about the shortage of the antiviral medication 'Remdesivir.' While the CDC claims to have sufficient stock, they have procured an additional 20,000 doses in response to the recent surge, expected to arrive on July 4. Concerns have also been raised about the risks of using the substitute medication 'Balavir,' potentially leading to strokes or myocardial infarctions among elderly patients with chronic conditions. The article highlights the challenges faced by healthcare facilities due to the medication shortages and the ongoing efforts to address the situation.
Source: YAHOO